The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A study of the recurrence score by the 21-gene signature assay as a predictor of clinical response to neoadjuvant exemestane for 24 weeks in estrogen-receptor-positive breast cancer.
N. Masuda
No relevant relationships to disclose
M. Toi
Honoraria - Pfizer
Research Funding - Pfizer
T. Ueno
No relevant relationships to disclose
T. Yamanaka
No relevant relationships to disclose
S. Saji
No relevant relationships to disclose
K. Kuroi
No relevant relationships to disclose
N. Sato
No relevant relationships to disclose
H. Takei
No relevant relationships to disclose
Y. Yamamoto
No relevant relationships to disclose
S. Ohno
No relevant relationships to disclose
H. Yamashita
No relevant relationships to disclose
K. Hisamatsu
No relevant relationships to disclose
K. Aogi
No relevant relationships to disclose
H. Iwata
No relevant relationships to disclose
S. Saji
No relevant relationships to disclose
H. Sasano
No relevant relationships to disclose